Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaMonoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentAn update on the management of chronic lymphocytic leukaemia.Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaPhase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.The spectrum of use of rituximab in chronic lymphocytic leukemiaRole of rituximab in first-line treatment of chronic lymphocytic leukemia.Antibody therapy for chronic lymphocytic leukemia.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712Choosing first-line therapy for chronic lymphocytic leukemia.Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders.Clinical use of rituximab in haematological malignancies.Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.Monoclonal antibody therapy of leukaemias and lymphomas.Recent advances in chronic lymphocytic leukemia.Fludarabine in chronic lymphocytic leukaemia.Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy.Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.Protective cancer immunotherapy: what can the innate immune system contribute?A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.Changing paradigms in the treatment of chronic lymphocytic leukemia.Chronic lymphocytic leukemia: putting new treatment options into perspective.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.Expanded use of rituximab in the management of non-Hodgkin lymphoma.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Detection methods of ZAP-70 in chronic lymphocytic leukemia.
P2860
Q24203027-B900C395-DEA8-4A0C-9CA2-B1A2BEF1592BQ24241519-81FC588F-E354-4FA4-85D5-8C61CE2CD9E5Q28082086-43AE497A-E2AC-49F4-9F6C-511954A0CCB5Q30341946-E8FC419C-F312-477C-B4F8-B8AB18ACA293Q33361984-FA456AE3-E81C-49AA-ADCF-A2AD38392DA5Q33375915-5FBA1DB0-0FDC-4360-82DE-3702CAD3B5AAQ33380135-9863A89D-E1CC-4CAE-ACCC-AC33A42E2B7BQ33382030-8FCACB97-E2AA-4B3C-98FE-CFD4999874EBQ33414468-DE21FC55-E0BB-4292-AF5F-3DA33E40BCC9Q33573355-5794628B-6456-4E3C-BF79-C8C7AA4F471AQ33880538-7FB047CD-CFB9-4787-AFDE-266EFF691F30Q34310845-0BB716EC-A457-492B-907F-14B69737DC34Q34510030-99CC1499-7690-494C-AB5F-ED78FC392606Q34574147-0EEC3264-5DE4-4C84-B792-ABF77FBEA253Q34589909-138B8169-5A20-4F5E-8244-E45363BCA063Q34700655-CCF2188A-2579-492D-B7F7-9EE9AAA05F2AQ34879367-22367525-8817-4D26-A038-50CFD764F4D7Q35124844-736B3F56-EC36-4142-9E80-FC33FEC849FCQ35430828-3F9B41A4-FBED-427F-9AE2-509A3D5D33ADQ35561014-11EEECC0-4802-4836-ACAA-C9A873C40314Q35626914-6003A0F3-EB61-4919-9B82-1E7EDD249C00Q35683808-D9F5B492-9E80-43F9-858A-528EE358A041Q35790006-5BB74174-22F8-4CBB-9C46-3F3B60298F45Q36218799-F1BBD969-5900-4581-ACD6-6F131C0FD95AQ36239669-819E7531-D072-40CE-99BE-70F5229218AEQ36523498-39D87F5C-60F9-44DE-BFF3-EC45F3AC425FQ36548735-241F9791-C0AD-42A4-8AF1-EE5DACF4090BQ36985872-E2CEF473-BD35-411C-BF30-ED4AE795F54BQ37031758-E5DBE8FE-F8A8-49DD-8919-49DA5214ADF0Q37032625-FC54FB9C-96A1-4AD0-BE67-1F54F03BC3FAQ37032632-8F21EF56-DDA8-4290-B3F5-DD53C08C28D8Q37364653-5FC2DA7B-CE66-4D60-A5D9-20821D293E3CQ37418477-21228FAC-5146-4A2C-8B90-E6D8A3E9D7F0Q37662198-3A543475-1598-4C9A-98C5-F1429F1C3543Q37734199-BAB63D24-336D-4E5A-93F3-1F35AA27F98BQ37767703-D9E6BB04-EEBC-4384-85E0-CAA554FEEFA9Q37771248-7C2D8891-A857-4212-B4FC-68BCC2164D00Q37799820-2695D660-DE63-4E0A-8C6C-0DE4A1B570E4Q37854714-46EBC115-A33E-42BA-9722-C4E7AA33910BQ37892409-95E5F064-A1D9-44D4-A359-3683D2858472
P2860
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Phase 2 study of a combined im ...... chronic lymphocytic leukemia.
@ast
Phase 2 study of a combined im ...... chronic lymphocytic leukemia.
@en
type
label
Phase 2 study of a combined im ...... chronic lymphocytic leukemia.
@ast
Phase 2 study of a combined im ...... chronic lymphocytic leukemia.
@en
prefLabel
Phase 2 study of a combined im ...... chronic lymphocytic leukemia.
@ast
Phase 2 study of a combined im ...... chronic lymphocytic leukemia.
@en
P2093
P1433
P1476
Phase 2 study of a combined im ...... chronic lymphocytic leukemia.
@en
P2093
Andreas Engert
Axel Hinke
Dieter Huhn
German CLL Study Group
Holger Schulz
Manfred Hensel
Marcel Reiser
Michael Herold
Saskia Karina Klein
Ute Rehwald
P304
P356
10.1182/BLOOD-2002-03-0972
P407
P577
2002-11-01T00:00:00Z